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1. Introduction 
The present chapter considers only one aspect of glucocorticoid therapy of patients with 
systemic lupus erythematosus (SLE): a possibility of using blood level of tyrosine for 
monitoring glucocorticoid therapy. Thus, problems of SLE etiology and pathogenesis, as 
well as numerous schemes of SLE therapy are beyond the limits of this chapter. In the 
сhapter normal catabolism of tyrosine and some congenital disturbances in catabolism of 
this amino acid are considered. But in the great majority of cases, specific features of 
tyrosine catabolism allow us to admit that tyrosine content in blood should be determined 
by the liver functional competence, in particular, its ability to synthesize an adaptive 
enzyme tyrosine aminotransferase and by entrance into the liver of glucocorticoids, natural 
hormones or glucocorticoid preparations. This сhapter also presents experimental data 
obtained on adrenalectomized rats and observations on children with adrenogenital 
syndrome which clearly demonstrate blood tyrosine dependence on glucocorticoids and 
support the idea of using blood tyrosine content as a promising laboratory parameter for 
monitoring glucocorticoid therapy, similar to blood glucose for insulin. Some observations 
on glucocorticoid therapy in patients with SLE compared with changes in their blood 
tyrosine level which were earlier published only in Russian are presented, as well as the 
imaginary tyrosine-based monitoring of these cases.  
2. Approaches to treatment of systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) seems to be the most striking example of using 
corticosteroid, or glucocorticoid, preparations in non-endocrine diseases as the most 
powerful anti-inflammatory, immunosuppressive, anti-allergic, antitoxic, etc. agents. Sixty 
years ago glucocorticoids allowed clinicians to radically change the fate of patients with SLE 
– this collagen disease stopped to be virtually lethal (Dubois, 1974; Schroeder & Euler, 1997; 
Ioannou & Isenberg, 2002; Goldblatt & Isenberg, 2005; Nived et al., 2008). In modern 
schemes of SLE treatment glucocorticoids are usually combined with various other 
preparations: cyclophosphamide, mycophenolate mofettil, rituximab, cyclosporine, 
azathioprine, etc. (Ntali et al., 2009; Ponticelli et al., 2010). In addition to their specific effects, 
all these preparations are given, in particular, in order to lower the dose of steroids, 
however, up to now glucocorticoids remain the cornerstone in the schemes of SLE 
treatment. Therefore, in SLE all problems associated with using glucocorticoid preparations 
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in non-endocrine diseases are clearly pronounced and still urgent: the unpredictability of 
efficiency of glucocorticoids and nearly inevitable serious side effects, difficulties and 
sometimes even the impossibility to abolish glucocorticoids, and glucocorticoid resistance of 
some patients – such was the situation at the beginning of the “steroid era” and it is nearly 
the same nowadays, and the same problems are still urgent. 
Since 1966, life-threatening exacerbations of SLE are sometimes treated by pulse-therapy – 
intravenous injection of very high doses of glucocorticoid preparations – up to 1 mg 
methylprednisolone daily for three days. However, the rapid immunosuppressive effect is 
often accompanied by various infections. But this regimen of pulse-therapy has been formed 
historically, although it is not excluded that lower doses of glucocorticoids would be 
similarly effective (Badscha & Edwards, 2003; Franchin & Diamond, 2006). 
It is obvious that the existent schemes of using glucocorticoids in SLE are far from optimal, and 
to specify and refine therapeutical approaches there are some attempts to compare the 
glucocorticoid efficiency in SLE with different individual characteristics of the patients, such as 
the number and type of glucocorticoid receptors (Li et al., 2010; Deng & Tsao, 2010; Oakley & 
Cidlowski, 2011), titers of antibodies to double-stranded DNA (Rahman & Isenberg, 2008), 
specific features of T- and B-cells, etc. It seems clear that responsiveness to glucocorticoids 
should be associated with some individual specific features of the patients. Moreover, 
glucocorticoid sensitivity is not steady in the same patient, but can vary from time to time and 
can be much more changeable than it has been believed earlier (De Rijk & Sternberg, 1997). 
It is rather strange but a very essential aspect of action of glucocorticoid preparations has been 
neglected during the whole period of using glucocorticoids in clinical medicine. It is extremely 
important that glucocorticoid preparations, as discriminated from all other pharmaceuticals 
used in the treatment of SLE, are synthetic copies of natural products of the organism – of 
glucocorticoid hormones synthesized in the adrenal cortex. Glucocorticoid preparations 
possessing the unique combination of therapeutic properties also inevitably retain the features 
of their natural prototypes, i.e. they are directly or indirectly involved in regulation of many if 
not all physiological processes and metabolic reactions and their using interferes the negative 
feedback regulation in the hypothalamus–pituitary–adrenocortical system. Therefore, it 
should be noted and emphasized that the inevitable complications of glucocorticoid therapy 
really are not “side effects”, on the contrary, they are natural manifestations of just hormonal 
properties of glucocorticoid preparations, either of their excess or of induced disorders in the 
feedback regulation of the hypothalamus–pituitary–adrenocortical system. Possibly, this 
neglecting was reasoned by a surprising and somewhat discouraging discovery in the 
beginning of “the glucocorticoid era” that the therapeutical effect of glucocorticoid 
preparations did not depend on the level of a patient’s own hormones?  
However, not the level of glucocorticoid hormones should be important, but the tissue 
provision with these hormones, especially on taking into account that glucocorticoids are 
hormones of virtually total action. Nevertheless, for glucocorticoids there is no parameter to 
characterize the tissue provision with these hormones (or with glucocorticoid preparations) 
and to determine the real need in them of a subject under various circumstances, in 
particular, under stress situations or in disease. This is especially important because 
glucocorticoids play a determinative role in stress situations. For glucocorticoids an indirect 
parameter is required which would be similar to blood glucose for insulin.  
Naturally, this parameter must be easily determinable in blood, have rather narrow normal 
limits in healthy persons, and clearly depend on glucocorticoids, natural hormones or 
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preparations. In particular, the glucocorticoid-dependent hepatic enzyme tyrosine 
aminotransferase and the resulting tyrosine level in blood which is directly determined by 
the activity of this enzyme deserve a special attention. 
3. Blood tyrosine levels in some non-endocrine diseases 
In the late 1950s Japanese researchers of the Nishimura group found increased levels of 
tyrosine in blood and urine of patients with collagen diseases (Nishimura et al., 1958; 
Nishimura et al., 1961) and supposed that disorders in tyrosine catabolism could be a 
biochemical basis of these diseases. These reports stimulated intensive studies on tyrosine 
catabolism in collagenoses and some other diseases, especially in Russia. As it was 
reasonably to expect, tyrosine catabolism was disturbed in patients with liver disorders, 
such as infectious hepatitis, chronic hepatitis, and liver cirrhosis, and blood tyrosine level 
was two-threefold increased in them (Levine & Kohn, 1967; Powell & Axelsen, 1972; 
Nordlinger et al., 1979). 
The hypothesis about the role of tyrosine catabolism disorders in pathogenesis of collagen 
diseases was not confirmed, but very interesting observations were described, in particular, 
by A.S. Kainova (Kainova, 1974): tyrosine levels in blood of patients with rheumatism 
decreased to normal values on successful hormonal and/or medicamentous therapy, and 
abolishment of glucocorticoid preparations in some cases was accompanied by an increase 
in the blood tyrosine level. 
4. Observations on blood tyrosine levels and glucocorticoid treatment in 
patients with SLE 
Systemic Lupus Erythematosus (SLE) was a problem for the Clinics of Therapy and 
Occupational Diseases, I Moscow Medical Institute, where I entered as a biochemist in 1968 
and had been working until 1978. Naturally, the disorders in tyrosine metabolism observed 
by Nishimura et al. in patients with collagen diseases and observations by Kainova on blood 
tyrosine changes in patients with rheumatism seemed to me a possible biochemical 
approach to start my study on SLE. 
Sixteen healthy donors (14 women and 2 men in the age from 20 to 40 years old) were used 
for determination the normal level of blood tyrosine, and it was found to be 16.2 ± 0.9 
µg/ml. Note, that the repeated measurements of blood tyrosine levels in the same donors 
gave virtually the same values, i.e. it occurred to be rather a stable parameter. 
Altogether 80 patients with SLE, 70 women and 10 men in the age range from 16 to 53 years 
old, were observed at 134 hospitalizations over the period of 19731976. Some patients were 
under observation repeatedly. The patients were not selected previously basing on their case 
history and severity and character of the disease. Tyrosine was determined in the serum 
from blood samples taken from patients with SLE at 8.00–8.30 a.m. on the empty stomach, 
usually once during 7-14 days over the period of hospitalization. The work was not a part of 
a previously approved plan of investigations, therefore, no blood samples were taken 
specially to determine the tyrosine content. Initially, levels of tyrosine and of its 
transamination product p-oxyphenylpyruvic acid were determined in parallel samples of 
blood and 24-h urine. The determination of tyrosine was performed spectrophotometrically 
by the method of Udenfriend & Cooper (1952), p-oxyphenylpyruvic acid was determined as 
described in the work (Knox & Pitt , 1957). It was shown that the increase in blood tyrosine 
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level was caused by disturbance in transamination (Rass, 1976), whereas the further stages 
of tyrosine oxidation in the patients under study were virtually unaffected.  
Changes in blood tyrosine in every patient were compared with the clinical and laboratory 
data recorded in their case histories after the patients’ discharge from the hospital, with a 
special attention to using glucocorticoid preparations, i.e. a kind of the retrospective 
experiment was performed. The results were published in Russian in the work (Rass et al., 
1977). Thirty-six patients were observed in the state of clinical remission; blood tyrosine was 
in normal limits in 23 of them and was steadily elevated in three patients (two of them had 
the affected liver); 28 patients obtained a supporting dose of glucocorticoids (not more than 
15 mg prednisolone per day).  
In 44 patients with SLE short-term “splashes” in blood tyrosine level were observed, and the 
retrospective analysis revealed that these “splashes” occurred simultaneously with some 
extraordinary events, such as a concurrent infection, aggravation of symptoms, or on the 
other day of a severe diagnostic procedure (e.g. the kidney biopsy), during the reaction to a 
new preparation, etc. Thus, these “splashes” were associated with a “stress-situation” when 
the need in glucocorticoid hormones was increased and in healthy subjects the synthesis of 
glucocorticoid hormones should increase. Thus, in a patient with chronic SLE who obtained 
5 mg/day prednisolone as a supporting dose over the period of 50 days of hospitalization 
blood tyrosine values were 25, 20, 22 µg/ml, and a “splash” to 53 µg/ml was recorded on 
the day after the diagnostic intravenous urography. At the other hospitalization two years 
later this patient obtained the daily dose of 10 mg prednisolone and had blood tyrosine level 
of 8 µg/ml (possibly, the supporting dose of 10 mg prednisolone/day was too high – the 
previous supporting dose of 5 mg/day seemed sufficient to maintain the level of blood 
tyrosine in normal limits of 20-25 µg/ml). Similar “splashes” in blood tyrosine level were 
also observed in patients with glomerulonephritis under similar situations. 
A very demonstrative was an attempt to even slightly lower the dose of glucocorticoid 
preparations in a clinically steroid-dependent patient with subacute SLE (Fig. 1). This 
“splash” in blood tyrosine was observed concurrently with the aggravation of her condition. 
In this patient the high background content of tyrosine was thought to be associated with 
the liver affection.  
 
 
Fig. 1. Changes in the blood tyrosine content in a clinically steroid-dependent 40-year-old 
patient with subacute SLE. The attempt to decrease the dose of prednisolone was associated 
with an aggravation of the patient’s condition. Dotted lines here and in the further Figures 
show normal limits of blood tyrosine contents.  
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“Splashes” in blood tyrosine were also observed in some patients with SLE at the  
alternate-day scheme of hormonal treatment on the next morning after glucocorticoid-free 
day. 
But comparing results of glucocorticoid therapy with the initial level and behavior of 
blood tyrosine in patients with SLE seems to be the most interesting and informative. 
Changes in blood tyrosine upon prescribing or increasing the dose of glucocorticoids (40-
60 mg/day calculated per prednisolone) because of SLE exacerbation were followed in 32 
patients. Glucocorticoid preparations were prescribed according to the conventional 
schemes. The post-discharge analysis of the case histories revealed that to 20 patients 
glucocorticoids were prescribed at the significantly increased level of blood tyrosine (49.1 
± 0.8 µg/ml as compared to 16.2 ± 0.9 µg/ml in 16 healthy donors) and an essential 
improvement of clinical and laboratory parameters was recorded in 17 of them. In 13 
patients this improvement was accompanied by a decrease in blood tyrosine, and this 
decrease was recorded before appearance of signs of Cushing’s syndrome; in four patients 
with markedly affected liver functions the level of blood tyrosine remained elevated 
although their general condition became somewhat better. It should be noted that the 
“improvement” in all cases concerned only parameters of SLE activity, and side effects 
were considered as inevitable. 
Twelve patients were given glucocorticoids on the background of normal blood tyrosine ( 
26.5 µg/ml); glucocorticoids were inefficient in nine of them, and in four patients signs of 
Cushing’s syndrome appeared very rapidly. Some improvement was recorded in three 
patients but this improvement could be due to other preparations given to them 
concurrently with glucocorticoids: azathioprine, heparin, cyclophosphamide, etc.  
Let us consider some real cases.  
Patient M., 27 years old, suffering from SLE for nine years was hospitalized because of 
aggravation of chronic SLE. Blood tyrosine at the first determination was 47.5 µg/ml.  
She was given prednisolone (30 mg/day) and antibiotics because of catarrhal  
state, however, 20 days later the immunologic activity was still present, as well as 
arthralgia and myalgia, blood tyrosine remains increased - 40 µg/ml; because of a 
continued aggravation of her condition 15 days later the prednisolone dose was increased 
to 40 mg/day, and in a week a pronounced clinical improvement was recorded, together with a 
decrease in the blood tyrosine level to normal (25 µg/ml). She received 40 mg/day 
prednisolone for 20 days, and then the lowering prednisolone dose was started – and 
blood tyrosine slightly increased. The patient was discharged with the improved clinical 
and laboratory data (Fig. 2).  
The following case (Fig. 3) presents a 21-year-old patient Zh., suffering of SLE during  
five years. She received long-term courses of prednisolone earlier in the maximal dose  
of 30 mg/day. A progressing osteonecrosis was observed. This time she was hospitalized 
because of an acute flare. At the first determination blood tyrosine level was somewhat 
increased (34.0 µg/ml), on the next day she was prescribed with prednisolone –  
45 mg/day, and this dose was maintained during 20 days. Five days after the beginning of 
glucocorticoid therapy blood tyrosine decreased to 20.0 µg/ml, and two days later a moon-
like face appeared and elevations of arterial pressure up to 170/100 mm Hg were recorded.  
GG therapy for 1.5 months was considered to be unfavorable; moreover, pains in  
femoral joints increased. Clinical improvement in this patient was obtained on  
prescribing heparin.  
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Fig. 2. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 




Fig. 3. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 
(hatched) in a 21-year-old patient with chronic SLE.  
Figure 4 shows changes in blood tyrosine level observed at withdrawal syndrome in a 22-
year-old patient P. with subacute SLE (Fig. 4). The patient was in the state of a relative 
clinical and laboratory remission at the supporting dose of prednisolone (15 mg/day) for 
rather a long time. Such a rapid abolishment of prednisolone at the hospitalization in 1974 
was forced by development of a pronounced aseptic osteonecrosis of femoral heads, and 
this abolishment was associated with a sharp aggravation of SLE symptoms associated with 
a sharp increase in blood tyrosine level. 
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Fig. 4. Blood tyrosine levels and regimen of glucocorticoid therapy in a patient with 
subacute SLE during two hospitalizations, at the state of relative remission in 1973, and at 
withdrawal syndrome in 1974. 
Thus, a certain association obviously occurred between the therapeutic effect of 
glucocorticoid preparations and their regulatory effect manifested by changes in the blood 
level of tyrosine. Moreover, such association cannot be occasional, exclusive, or SLE-specific, 
because the dependence of tyrosine catabolism on glucocorticoids is fundamentally the 
same in humans and in other mammals. Such an association must be significantly most 
common. In particular, blood tyrosine level was also increased in patients with bronchial 
asthma (not receiving glucocorticoids) during the period of attacks and was normal during 
the state of remission (Rass et al., 1978). 
If so, may be blood tyrosine content can be used as a representative index of action of 
glucocorticoid hormones on metabolism, as an index of tissue provision with these 
hormones, and of real need of a subject in these hormones? May be blood tyrosine level can 
be used as a parameter (index) of glucocorticoid action, similarly to blood glucose which is a 
parameter of insulin action? 
5. Tyrosine catabolism and blood tyrosine level as an index of glucocorticoid 
hormone action  
This idea induced by observations on changes in blood tyrosine levels and regimens of 
glucocorticoid therapy in patients with SLE was for the first time published in the above-
mentioned work (Rass et al., 1977) and was theoretically considered in the paper (Rass, 
1978); then this idea was confirmed by experimental studies on adrenalectomized rats (Rass, 
1980; Rass, 1983) and by observations on children with adrenogenital syndrome receiving 
long-life substitutive glucocorticoid therapy (Rass et al., 1979). In 1991 the hazard of 
glucocorticoid hormone application in non-endocrine diseases was considered to be mainly 
due to the absence of a test for sufficiency and real need in these hormones, and 
introduction of blood tyrosine as such a test was proposed as a safety basis for the 
individualized strategy of glucocorticoid therapy (Piruzian & Rass, 1991). However, all 
www.intechopen.com
 Systemic Lupus Erythematosus 
 
170 
these works were published only in Russian, and this apparently promising idea remained 
virtually not called for until the review (Rass, 2010) was published in English. 
Let us consider some specific features of tyrosine catabolism, especially those which allow 
us to consider the blood level of this amino acid as a promising laboratory parameter for 
monitoring glucocorticoid therapy. 
Tyrosine is produced in the organism as a result of hydrolysis of food protein immediately 
or after hydrolysis of phenylalanine. About 30% of produced tyrosine is used for synthesis 
of catecholamines, melanin, and thyroid hormones, a portion is used for renewal of tissue 
proteins, and more than 60% is oxidized in the liver (Knox, 1955). And the first reaction in 
the major oxidation pathway of tyrosine is its transamination with alpha-ketoglutaric acid 
under the influence of tyrosine aminotransferase with production of p-oxyphenylpyruvic 
acid. Then p-oxyphenylpyruvic acid is oxidized under the influence of the appropriate 
oxidase in the presence of ascorbic acid with production of 2,5-dioxyphenylpyruvic, or 
homogentisic acid. The terminal products of the major pathway of tyrosine oxidation are 
acetoacetic and fumaric acids (Fig. 5). 
Most frequently, tyrosine content in blood is determined using its reaction with  
alpha-nitroso-beta-naphthol with a subsequent recording by spectrophotometry 
(Udenfriend & Cooper, 1952) or by fluorimetry (Grenier & Laberge, 1974; Gavrilov et al., 
1998). In some works HPLC (Kand’ar & Zakova, 2009), ion-exchange chromatography 
(Allard et al., 2004), and gas chromatography – mass-spectrometry (Deng et al., 2002) are 
also used. In some of the above-listed works tyrosine was determined in blood samples 
dried on filter paper discs.  
The interest for determination of tyrosine level in blood is caused by necessity of early 
diagnosis of congenital disturbances of phenylalaninetyrosine catabolism which result in 
severe disorders in the mental and physical development of the affected children. 
Phenylketonuria is caused by deficiency of the enzyme phenylalanine hydroxylase and is 
characterized by an extremely low level of blood tyrosine (< 0.05 µg/ml), tyrosinosis which 
is caused by an insufficient elimination of p-oxyphenylpyruvate acid due to deficiency of the 
appropriate oxidase (Scriver, 1967; Cerone at al., 1997) is manifested by a stable 
hypertyrosinemia up to 100 µg/ml, and in Richner–Hanhart syndrome caused by an inborn 
insufficiency of tyrosine aminotransferase blood tyrosine level can reach 600 µg/ml 
(Goldsmith, 1978; Natt et al., 1992). Incidence of phenylketonuria throughout the world is, 
on average, 1 : 15’000, and of the two other disorders in tyrosine catabolism are, 
respectively, 1 : 100’000 and 1 : 250’000, but in Canada they are recorded more frequently.  
Tyrosine aminotransferase is an adaptive enzyme synthesized by the liver cells in response 
to entrance of the substrate – tyrosine, but for the substrate induction of this enzyme the 
entrance of glucocorticoids in the liver is necessary (Rosen and Nichol, 1963; Gelehrter, 1973; 
Thompson, 1979). Synthesis of hepatic tyrosine aminotransferase is a well-known example 
of the so-called gene-mediated action of glucocorticoids, and this enzyme is the most 
demonstrative and beloved object for studies of such effects of glucocorticoids (Sun at al., 
1998; Grange et al., 2001; Hazra et al., 2007). Tyrosine aminotransferase is also used for 
testing on cell cultures and on intact and adrenalectomized animals of newly synthesized 
preparations which are expected to have less adverse effects than “classic” glucocorticoid 
preparations (Schacke et al., 2004; Zimmermann et al., 2009). The synthesis of tyrosine 
aminotransferase quantitatively depends on glucocorticoids, but being a hepatic enzyme, it 
cannot be determined in blood. However, tyrosine aminotransferase is a key enzyme in the 
major pathway of tyrosine catabolism and its activity determines the level of free tyrosine in 
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blood. As a result, blood tyrosine level also depends on glucocorticoids (and, naturally, also 
on the functional competence of the liver cells). 
 
 
Fig. 5. Tyrosine catabolism (Scheme).  
Due to substrate induction of tyrosine aminotransferase, even on tenfold increase in protein 
amount in the diet the blood content of tyrosine increases no more than by 50% above the 
basal level (Scriver et al., 1971), whereas circadian variations in blood tyrosine level mainly 
depending on circadian variations in production of natural glucocorticoids are in the limit  
of ± 25% (Wurtman et al., 1968).  
www.intechopen.com
 Systemic Lupus Erythematosus 
 
172 
But in the majority of cases and under real conditions an increase in blood tyrosine can be 
mainly determined by two factors: 1) a functional inferiority of the liver leading to a 
disturbed reception of glucocorticoids and inability of the liver cells to synthesize some 
enzymes including tyrosine aminotransferase, and 2) an insufficient entrance of 
glucocorticoids in the liver. As a result, under conditions of physiological rest, in the 
absence of extreme fluctuations in the diet, and on determination on the empty stomach in 
the morning the levels of free tyrosine in blood are similar in healthy animals and humans 
and do not depend on age and sex (Table 1).  
 
Subjects under study The number of subjects g/ml 
Men 91 13.0 ± 2.7 
Women 103 12.3 ± 2.4 
Boys 6-18 yr 75 12.3 ± 1.8 
Girls 6-18 yr 65 11.4 ± 2.0 
Table 1. Blood tyrosine levels in humans, after (Armstrong & Stave, 1973a) 
Moreover, it should be noted that blood samples taken from the same subjects (35 boys and 
26 girls) four times over the period of 33½ years displayed characteristic individual 
patterns for the most of plasma amino acids, in particular, the content of blood tyrosine was 
virtually constant in the same subject (Armstrong & Stave, 1973b). We have also observed 
virtually the same values of blood tyrosine level in the samples taken repeatedly from the 
same healthy donors, as well as in blood samples from patients with SLE on supporting 
dose of glucocorticoids in the state of remission.  
Injection of glucocorticoid preparations induced a 2040% dose-dependent decrease in 
blood tyrosine in both animals and humans (Rivlin & Melmon, 1965; Betheil et al., 1965), 
and this decrease was the most pronounced 4-5 h after the injection, i.e. at the maximum of 
the glucocorticoid-induced synthesis of tyrosine aminotransferase. A decrease in the content 
of blood tyrosine was also recorded under stress conditions (Nemeth, 1978), obviously, due 
to a well-known increase in the glucocorticoid production by the adrenal cortex. Effects of 
hydrocortisone injection to healthy volunteers recorded by changes in the blood tyrosine 
levels and in the peripheral lymphocyte counts were considered as manifestations of 
genomic and nongenomic effects of glucocorticoids, respectively (Derks et al., 1999). 
It is interesting to note that injections of hepatotoxins caused in rats an increase in the level 
of blood tyrosine, and the more pronounced was the liver necrosis the higher was this 
increase (Clayton et al., 2007).  
6. Blood tyrosine content is an index of tissue provision with 
glucocorticoids: Confirmation on the experimental and clinical models 
The dependence of blood tyrosine content on glucocorticoids was demonstrated 
experimentally on adrenalectomized rats (Rass, 1980; Rass, 2010). In intact rats blood 
tyrosine level was 15.0 ± 1.4 µg/ml. After bilateral adrenalectomy the blood level of tyrosine 
began to increase and reached, on average, 37.9 ± 6.4 µg/ml on the 5th day concurrently with 
the worst condition of the animals; then blood tyrosine level began to decrease most likely 
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due to synthesis of corticosterone in the brown fat tissue in response to the increased 
synthesis of ACTH after adrenalectomy; on the 10th day blood tyrosine level was the same 
as initially (under conditions of physiological rest!). Thus, the tyrosine level in blood 
manifested a pronounced dependence on production of natural glucocorticoids. 
Starting from the 7th day after the operation, adrenalectomized rats were injected daily 
intraperitoneously with hydrocortisone in the dose of 2 mg per kg body weight (this  
dose approximately corresponded to the supporting dose 15 mg/day of prednisolone). 
Daily injections of hydrocortisone during 20 days resulted in a decrease in the tyrosine level 
in blood to undeterminable level, the abolishment of the injections and their absence during 
5 days caused an increase in blood tyrosine, and the recommencement of hydrocortisone 




Fig. 6. Changes in tyrosine content in blood of adrenalectomized rats subjected to daily 
injections of hydrocortisone (hatched), upon abolishment of the injections, and on their 
recommencement.  
And it seems that the only clinical situation exists (the model was recommended by Prof. 
M.A. Zhukovsky) which allows a physician (endocrinologist) to control the entrance of 
glucocorticoids in the organism and to some degree assess the adequacy of tissue 
provision with glucocorticoids to real needs of just this patient. This unique situation is 
presented by adrenogenital syndrome (synonyms: congenital adrenal hyperplasia, 
congenital virilizing adrenal cortex dysfunction) in children. The disease is caused by a 
genetically determined deficiency of glucocorticoid biosynthesis enzymes in the adrenal 
cortex, most frequently of 21-beta-hydroxylase, and a resulting shift to synthesis of 
androgens, mainly of dehydroepiandrosterone. The decreased production of 
glucocorticoids induces an increased synthesis of ACTH in the adenohypophysis that 
permanently stimulates the adrenal cortex with a resulting surplus synthesis of androgens 
(Brooks, 1979). The excess of androgens is displayed by a characteristic clinical picture: an 
abnormal structure of external sex organs, an accelerated body growth with an 
overdevelopment of masculine type muscles during the first years of life, the early 
arresting of growth because of premature ossification of tubular bones, etc. In the affected 
girls a picture of pseudohermaphroditism is developed. 
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The lifelong substitutive glucocorticoid therapy is the only pathogenetically reasonable 
treatment of this disease (Lo et al., 1999; Stikkelbroeck et al., 2003; Hughes, 2007). 
Glucocorticoid preparations break the vicious circle: recompensing the shortage of 
endogenous glucocorticoids they inhibit synthesis of ACTH responsible for overproduction 
of androgens. Glucocorticoid therapy started as early as possible after the birth and the 
appropriate dose can provide the normal physical and sexual maturation of the affected 
children according to their genetic sex, with a possibility of normal pregnancy and labor in 
females. The dose of glucocorticoids must be strictly individualized, and it can vary from 2.5 
to 15 mg prednisolone per day.    
On the other hand, changes in the clinical picture observed in children with adrenogenital 
syndrome – the rate of growth, ossification, and sexual maturation – allow a physician to 
relatively objectively and faultlessly estimate the correctness of the dose. In adult patients 
with this syndrome and in other conditions which obviously require the substitutive 
glucocorticoid therapy, after bilateral adrenalectomy or in chronic hypocorticism of 
various etiology, the dose of glucocorticoids can be prescribed only “according to the 
patient’s self-feeling”. According to B. Lukert (Lukert, 2006), “The problem for the 
clinician is the lack of objective criteria for determining adequate, but not excessive doses 
of glucocorticoids… In current practice, the clinician must rely on surrogate markers of 
glucocorticoid excess (early changes of Cushing’s syndrome) rather than definitive end 
points”.  
Our study was performed with participation of 38 children with virilizing adrenogenital 
syndrome (33 girls and five boys of 318 years old hospitalized in the Pediatric Department 
of the Institute of Experimental Endocrinology and Chemistry of Hormones, the USSR 
Academy of Medical Sciences). Tyrosine levels were determined in blood samples taken in 
the morning on empty stomach and compared with clinical picture which characterized the 
degree of compensation of the genetic defect. The results were published in Russian (Rass et 
al., 1979) and republished in English in the review (Rass, 2010). The main results are 
presented in Fig. 7. 
Figure 7 shows that in 17 children with adrenogenital syndrome at the complete clinical 
compensation blood contents of tyrosine were the same as in healthy donors (16 adults and 
seven children of 713 years old). In a girl with signs of Cushing’s syndrome blood tyrosine 
was below the normal level. In untreated patients and in non-compensated patients because 
of irregular treatment blood tyrosine was significantly increased. In three non-compensated 
patients a pronounced melanodermia was observed along with the normal level of blood 
tyrosine, i.e. a part of excessive tyrosine was not oxidized through the major pathway but 
was converted into melanin (compare with the Scheme in Fig. 5!). Prescribing 
glucocorticoids resulted in “whitening” of such patients. Normalization of skin color in 
patients with hypocorticism upon taking glucocorticoids was also described in the literature 
(Snell, 1967).  
In two compensated patients who initially displayed normal levels of blood tyrosine, 
transient increases to 29.0 and 45.0 µg/ml were recorded in association with a concurrent 
acute respiratory disease. Obviously, these increases are very alike “splashes” observed in 
patients with SLE, and can be explained by increased requirements for glucocorticoid 
hormones under conditions of stress or concurrent disease. Such observations justify the 
empirical recommendation to increase the dose of glucocorticoid preparations in the case of 
stress situations. 
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Two previously untreated girls were prescribed with glucocorticoids, and the 
determinations of blood tyrosine levels were helpful for choosing the optimal dose. Note 
that in patients with hypocorticism an acute withdrawal of the substitutive hydrocortisone 
injections resulted on the next day in a 25-30% increase in the level of blood tyrosine, 
whereas the levels of other amino acids remained virtually unchanged (Christiansen et  
al., 2007). The data presented in this section show that the normal level of blood tyrosine 
seems to indicate a sufficient provision of tissues and glucocorticoid-dependent reactions 
and processes with these hormones, whereas an increased level of blood tyrosine seems  




Fig. 7. Tyrosine contents in blood of healthy donors and children with adrenogenital 
syndrome. The columns present arithmetic means for the corresponding groups; the circles 
show individual values: I) healthy adults; II) healthy children; III) patients with the 
complete clinical compensation; IV) a girl patient with overdosed glucocorticoids; V) 
irregularly treated non-compensated patients; VI) untreated patients. Hatched circles in the 
columns V and VI show patients with a pronounced melanodermia. 
However, it is also reasonable to expect that blood content of tyrosine could be a promising 
candidate for the role of an indirect marker for prescribing the correct dose in non-endocrine 
diseases. Unfortunately, for non-endocrine diseases there are no similar data, nevertheless, 
let us admit that blood tyrosine level could be used as an index of tissue provision and real 
need in glucocorticoid hormones (or glucocorticoid preparations) – in our patients with SLE 
described in the Section 4.      
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7. The imaginary tyrosine-based monitoring of glucocorticoid therapy in  
the above-presented cases of SLE (reconsideration of cases presented  
in Figs. 24)  
Thus, keeping in mind the blood tyrosine as an index of the real need in glucocorticoids, let 
us look again at Figs. 24 and imagine the tyrosine-based monitoring of glucocorticoid 
treatment in these patients with SLE.  
Fig. 2  the imaginary monitoring. The patient M. was prescribed with 30 mg prednisolone 
daily on the background of a rather high initial level of blood tyrosine (47.5 µg/ml);  
she received this dose during 35 days without a pronounced clinical effect and on 
retention of the increased blood tyrosine (40.0 µg/ml). The improvement was achieved as 
soon as a week after increasing the prednisolone dose to 40 mg/day and this 
improvement was accompanied by normalization of blood tyrosine. The patient 
continued to receive 40 mg prednisolone for the following 15 days. Thus, in total,  
the patient M. received 30-40 mg prednisolone daily within two months. But, taking into 
account the initial high level of blood tyrosine, as well as its retention at the second 
determination 20 days later, it would have been reasonable to give her 40 mg prednisolone 
earlier and to start lowering the dose on normalization of blood tyrosine, i.e. the course of hormonal 
therapy could be much shorter. 
Fig. 3  the imaginary monitoring. The increased level of blood tyrosine (34 µg/ml) at the first 
determination on the next day after the hospitalization could be a kind of “splash” – the 
reaction to hospitalization-associated procedure. The patient was prescribed 45 mg 
prednisolone per day and obtained this dose for 20 days. Blood tyrosine became normal 
very rapidly – on the 5th day after the hospitalization (even earlier than the recorded in the case 
history appearance of the moon-like face and elevations in blood pressure!) and continued to 
decrease to very low level during the treatment with glucocorticoids. After 1.5 months, 
glucocorticoid therapy was qualified as unfavorable. Was it a case of steroid-resistance or 
simply a manifestation of a sufficient provision with own hormones? In any case, this patient 
did not need such a prolonged and rather intensive glucocorticoid therapy. 
Fig. 4  the imaginary monitoring. Withdrawal syndrome in a 22-year-old patient with 
subacute SLE. The normal blood tyrosine level during the hospitalization the year before at 
the supporting dose of prednisolone 15 mg/day made it possible to think about at least of 
decreasing the supporting dose of glucocorticoids, or even of trying to abolish hormonal preparations 
the year earlier! 
8. And the real successful course of glucocorticoid therapy  
without side effects  
The next case (Fig. 8) exemplifies a successful course of glucocorticoid therapy performed by 
Dr. I.A. Borisov (described in detail in the work (Rass et al., 1977)) in a 48-year-old patient E. 
who had been suffering of SLE for 12 years. This hospitalization was because of a serious 
flare of SLE after an acute respiratory disease. All previous courses of glucocorticoids in this 
patient resulted in a rapid development of Cushing’s syndrome. On the entrance blood tyrosine 
was 45–79 µg/ml. She was given prednisolone (40 mg/day) within a week and then 
transferred to alternate-day scheme of the dose lowering (the increase in blood tyrosine to 
100 µg/ml was recorded in the morning two days after the abolishment of daily 
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prednisolone). The alternate-day scheme was started from daily dose of 75 mg with a 
stepwise decreasing to 25 mg/day (combined with methindol on prednisolone-free days). 
Blood tyrosine decreased to the normal level (16 µg/ml) alongside with a general 
improvement of all clinical and laboratory data. The increase in the blood tyrosine level to 
35 µg/ml concurrently with the SLE activation was recorded when prednisolone was 
replaced by decortilene; then a respiratory disease was associated with blood tyrosine 
increases to 30–45 µg/ml; and prednisolone was prescribed again in the daily dose of 30 mg 
during a week followed by the alternate-day lowering the prednisolone dose starting from 




Fig. 8. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 
(hatched) in a 48-year-old patient with SLE. 
It should be underlined that in this case two specific hormonal features of the glucocorticoid 
preparations were taken into account: the organism’s provision with glucocorticoids 
characterized by blood tyrosine level and using the alternate-day scheme for lowering the 
dose of hormonal preparation dose to promote the recovery of the negative feedback 
regulation in the hypothalamus-pituitary-adrenocortical system.  
9. Conclusion 
Preparations of glucocorticoid hormones for more than 60 years remain one of cornerstones 
of modern medicine as the most effective anti-inflammatory drugs also possessing anti-
allergic, immunosuppressive, antitoxic, and anti-shock properties. Glucocorticoid 
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preparations are widely used in all fields of clinical medicine and are virtually 
indispensable, although very serious complications are associated with their application. 
The number of works concerning glucocorticoid treatment of various diseases is 
innumerable. However, despite the extreme importance and indispensability of 
glucocorticoid preparations, up to now there is no objective laboratory parameter, similar to 
blood glucose for insulin, which would allow a clinician to foresee the effect of hormonal 
therapy in a given patient and realize a reasonable monitoring of the dose of glucocorticoid 
preparations.  
The problem of safety of glucocorticoid therapy arose concurrently with the first usage of 
glucocorticoids by Dr. P. Hench and colleagues in 1948 (Hench et al, 1949) and difficulties 
which should be inevitable on using glucocorticoids were predicted and described in their 
large publication (Hench et al., 1950). Unfortunately, multiple refined studies on 
glucocorticoids by biochemists, geneticists, endocrinologists, physiologists, although very 
informative, are not frequently intersected with real need of clinical medicine.  
Just the permanent critical state of glucocorticoid therapy made me reconsider my old 
works published in Russian in 19761983 which remained unnoticed and unknown. And 
only the publication in English (Rass, 2010) has attracted the attention to the still urgent 
problem of absence of a laboratory parameter extremely required for glucocorticoid therapy 
of both endocrine and non-endocrine diseases.  
I hope that rather an easy determination of blood tyrosine level will be at last used as a 
suitable laboratory parameter for many situations in clinical medicine, endocrinology, and 
physiology of the hypothalamus–pituitary–adrenal cortex system. In physiology blood 
tyrosine determination can supplement measurements of levels of the hormonal participants 
of this system by data on adequacy of this system functioning to the organism’s needs under 
different situations. 
And finally some speculations.  
The comparison of therapeutic effect of glucocorticoid preparations in SLE with their 
regulatory influence on the blood tyrosine level suggests that the therapeutic action of these 
preparations cannot be conditioned by an exclusive combination of pharmacological 
properties; on the contrary, the unique combination of therapeutic properties of these 
preparations is caused by retention of specific hormonal properties.  
Glucocorticoid hormones are essentially responsible for supporting homeostasis – they 
directly or indirectly participate in regulation of the majority (if not all) biochemical 
reactions and physiological processes. They are hormones of total action and of vital 
importance. But in addition to supporting homeostasis under conditions of health and 
physiological rest, glucocorticoid hormones play a very important and sometimes a decisive 
role under conditions of stress or disease when, as a rule, their secretion increases. Under 
stress situations or in disease glucocorticoid hormones can realize their effects acting via the 
evolutionary selected best pathways, and, no doubt, a certain optimum of the adrenal cortex 
activity must exist for every subject (a human or animal) under extraordinary conditions. 
However, it seems that the optimum of this individual adrenocortical response can be 
revealed not by determination of functions of the hypothalamus-pituitary-adrenocortical 
system links, but only using a result of this system activity - an indirect glucocorticoid-
dependent parameter, which can indicate whether this response is sufficient or not just for 
the concrete subject in a specific situation.  
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Glucocorticoid preparations retain the fundamental features of their natural prototypes, 
including their physiological and regulatory functions and can act via the same pathways. 
Therefore, it seems very likely that glucocorticoid therapy in non-endocrine diseases must 
imitate the optimal hormonal response of a given patient under conditions of disease – as if 
his adrenals could realize such a response. Glucocorticoid therapy must compensate an 
insufficient response of the patient’s own adrenals, it can be life-saving within these limits 
and dangerous beyond them. The determination of blood tyrosine level which is a 
manifestation of the regulatory effect of glucocorticoid can allow a clinician to assess the 
correspondence of the hormonal provision to real needs of the patient.  
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